Literature DB >> 29628498

Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer.

Si-Si Wang1, Wei Liu2,3, Dalam Ly4,5, Hao Xu1, Limei Qu6, Li Zhang7,8.   

Abstract

Evidence indicates that lung cancer development is a complex process that involves interactions between tumor cells, stromal fibroblasts, and immune cells. Tumor-infiltrating immune cells play a significant role in the promotion or inhibition of tumor growth. As an integral component of the tumor microenvironment, tumor-infiltrating B lymphocytes (TIBs) exist in all stages of cancer and play important roles in shaping tumor development. Here, we review recent clinical and preclinical studies that outline the role of TIBs in lung cancer development, assess their prognostic significance, and explore the potential benefit of B cell-based immunotherapy for lung cancer treatment.

Entities:  

Keywords:  B cells; Bregs; immunotherapy; lung cancer; tumor-infiltrating B cells

Mesh：

Year:  2018        PMID： 29628498      PMCID： PMC6318290          DOI： 10.1038/s41423-018-0027-x

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN： 1672-7681            Impact factor:   11.530


  97 in total

1.  Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue.

Authors:  D Schrama; P thor Straten; W H Fischer; A D McLellan; E B Bröcker; R A Reisfeld; J C Becker
Journal:  Immunity       Date:  2001-02       Impact factor: 31.745

2.  Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where plasmablasts mature.

Authors:  Elodie Mohr; Karine Serre; Rudolf A Manz; Adam F Cunningham; Mahmood Khan; Deborah L Hardie; Roger Bird; Ian C M MacLennan
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

3.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

Authors:  Marie-Caroline Dieu-Nosjean; Martine Antoine; Claire Danel; Didier Heudes; Marie Wislez; Virginie Poulot; Nathalie Rabbe; Ludivine Laurans; Eric Tartour; Luc de Chaisemartin; Serge Lebecque; Wolf-Herman Fridman; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

4.  De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.

Authors:  Karin E de Visser; Lidiya V Korets; Lisa M Coussens
Journal:  Cancer Cell       Date:  2005-05       Impact factor: 31.743

5.  Lung and splenic B cells facilitate diverse effects on in vitro measures of antitumor immune responses.

Authors:  Harlan P Jones; Yi-Chong Wang; Beau Aldridge; Jay M Weiss
Journal:  Cancer Immun       Date:  2008-02-19

6.  Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor α.

Authors:  Katarzyna Wejksza; Catalina Lee-Chang; Monica Bodogai; Jessica Bonzo; Frank J Gonzalez; Elin Lehrmann; Kevin Becker; Arya Biragyn
Journal:  J Immunol       Date:  2013-02-13       Impact factor: 5.422

7.  Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.

Authors:  Kevin Chu Foy; Ruthie M Wygle; Megan J Miller; Jay P Overholser; Tanios Bekaii-Saab; Pravin T P Kaumaya
Journal:  J Immunol       Date:  2013-05-22       Impact factor: 5.422

8.  RETRACTED: Aberrant frequency of IL-10-producing B cells and its association with Treg and MDSC cells in Non Small Cell Lung Carcinoma patients.

Authors:  Jinlin Liu; Huan Wang; Qinhua Yu; Sujie Zheng; Yangcheng Jiang; Yiyan Liu; Guorong Yuan; Liannv Qiu
Journal:  Hum Immunol       Date:  2015-10-23       Impact factor: 2.850

9.  Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue.

Authors:  David Schrama; Heike Voigt; Andreas O Eggert; Rong Xiang; He Zhou; Ton N M Schumacher; Mads H Andersen; Per thor Straten; Ralph A Reisfeld; Jürgen C Becker
Journal:  Cancer Immunol Immunother       Date:  2007-06-29       Impact factor: 6.968

Review 10.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Authors:  Suzanne L Topalian; Janis M Taube; Robert A Anders; Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716
View more
  115 in total

Review 1.  Immunosenescence: a key player in cancer development.

Authors:  Jingyao Lian; Ying Yue; Weina Yu; Yi Zhang
Journal:  J Hematol Oncol       Date:  2020-11-10       Impact factor: 17.388

Review 2.  Therapeutic cancer vaccines.

Authors:  Mansi Saxena; Sjoerd H van der Burg; Cornelis J M Melief; Nina Bhardwaj
Journal:  Nat Rev Cancer       Date:  2021-04-27       Impact factor: 60.716

3.  Deceleration of glycometabolism impedes IgG-producing B-cell-mediated tumor elimination by targeting SATB1.

Authors:  Jiajing Liu; Yifan Li; Zhou Lu; Jie Gu; Yun Liang; Enyu Huang; Zhiming Wang; Hushan Zhang; Luman Wang; Dan Zhang; Hongxiu Yu; Ronghua Liu; Yiwei Chu
Journal:  Immunology       Date:  2018-10-10       Impact factor: 7.397

4.  Development of Cancer Immunotherapies.

Authors:  Diana C DeLucia; John K Lee
Journal:  Cancer Treat Res       Date:  2022

5.  Local and Systemic Antitumor Effects of Photo-activatable Paclitaxel Prodrug on Rat Breast Tumor Models.

Authors:  Bharathiraja Subramaniyan; Pallavi Rajaputra; Luong Nguyen; Mengjie Li; Cody J Peer; Jessica Kindrick; William D Figg; Sukyung Woo; Youngjae You
Journal:  Photochem Photobiol       Date:  2020-03-09       Impact factor: 3.421

6.  Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing.

Authors:  Ansam Sinjab; Guangchun Han; Warapen Treekitkarnmongkol; Kieko Hara; Patrick M Brennan; Minghao Dang; Dapeng Hao; Ruiping Wang; Enyu Dai; Hitoshi Dejima; Jiexin Zhang; Elena Bogatenkova; Beatriz Sanchez-Espiridion; Kyle Chang; Danielle R Little; Samer Bazzi; Linh M Tran; Kostyantyn Krysan; Carmen Behrens; Dzifa Y Duose; Edwin R Parra; Maria Gabriela Raso; Luisa M Solis; Junya Fukuoka; Jianjun Zhang; Boris Sepesi; Tina Cascone; Lauren Averett Byers; Don L Gibbons; Jichao Chen; Seyed Javad Moghaddam; Edwin J Ostrin; Daniel Rosen; John V Heymach; Paul Scheet; Steven M Dubinett; Junya Fujimoto; Ignacio I Wistuba; Christopher S Stevenson; Avrum Spira; Linghua Wang; Humam Kadara
Journal:  Cancer Discov       Date:  2021-05-10       Impact factor: 39.397

Review 7.  B cell heterogeneity, plasticity, and functional diversity in cancer microenvironments.

Authors:  Yuan Wei; Chun-Xiang Huang; Xiao Xiao; Dong-Ping Chen; Hong Shan; Huanhuan He; Dong-Ming Kuang
Journal:  Oncogene       Date:  2021-06-29       Impact factor: 9.867

8.  Inflammation and tumor progression: signaling pathways and targeted intervention.

Authors:  Huakan Zhao; Lei Wu; Guifang Yan; Yu Chen; Mingyue Zhou; Yongzhong Wu; Yongsheng Li
Journal:  Signal Transduct Target Ther       Date:  2021-07-12

9.  A Pan-Cancer Analysis of the Oncogenic Role of Twinfilin Actin Binding Protein 1 in Human Tumors.

Authors:  Gengwei Huo; Yali Wang; Jinliang Chen; Ying Song; Cuicui Zhang; Hua Guo; Ran Zuo; Fuyi Zhu; Jinfang Cui; Weidong Chen; Wenming Chen; Peng Chen
Journal:  Front Oncol       Date:  2021-05-25       Impact factor: 6.244

10.  Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC.

Authors:  Kwan Ho Tang; Shuai Li; Kwok-Kin Wong; Benjamin G Neel; Alireza Khodadadi-Jamayran; Jayu Jen; Han Han; Kayla Guidry; Ting Chen; Yuan Hao; Carmine Fedele; John A Zebala; Dean Y Maeda; James G Christensen; Peter Olson; Argus Athanas; Cynthia A Loomis; Aristotelis Tsirigos
Journal:  Cancer Discov       Date:  2021-08-05       Impact factor: 39.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.